{"id":8591,"date":"2020-02-25T16:46:20","date_gmt":"2020-02-25T11:16:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8591"},"modified":"2021-07-24T12:57:48","modified_gmt":"2021-07-24T07:27:48","slug":"recent-pharma-happenings-for-lundbeck-esperion-karius","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius","title":{"rendered":"US approval to Lundbeck\u2019s Vyepti for preventive migraine care; Esperion\u2019s cholesterol-lowering drug Nexletol receives FDA nod; Karius \u2013 a start-up company \u2013 raises USD 165 Million \u2013 strengthens it liquid biopsy testing"},"content":{"rendered":"\n

Formerly known as eptinezumab, Lundbeck\u2019s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. <\/strong><\/h2>\n\n\n\n

Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine<\/a>.\u00a0<\/p>\n\n\n\n

With the green signal to Lundbeck, it becomes a new member in the Migraine treatment market<\/a>, which is already swarming with the new therapies by pharma giants including Teva, Amgen and Eli Lilly.\u00a0<\/p>\n\n\n\n

Vyepti<\/strong> is the very first intravenous medication to receive the approval and will be available to patients from April this year. A humanized monoclonal antibody, Vyepti binds to calcitonin gene-related peptide (CGRP) ligand thus blocking its binding to the receptor. So far, anti-CGRP drug treatment<\/strong> has been the mainstay in the Migraine treatment market.\u00a0Acquired from Alder Biopharmaceuticals, the drug is going to fiercely compete with Teva\u2019s Ajovy<\/strong>, Amgen\u2019s Aimovig<\/strong> and Lilly\u2019s Emgality<\/strong>. <\/p>\n\n\n\n

Michigan-based lipid management company- Esperion has announced the US FDA nod for its LDL-cholesterol lowering drug Nexletol. <\/strong><\/h2>\n\n\n\n

A once-daily, first-in-class ATP Citrate Lyase (ACL) inhibitor, Nexletol<\/strong> (bempedoic acid) lowers down the LDL-Cholesterol <\/a>(LDL-C) by halting the synthesis of cholesterol in the liver<\/a>. The first-ever oral therapy, Nexletol<\/strong> has been recommended for treating patients with heterozygous familial hypercholesterolemia (HeFH)<\/a> or established atherosclerotic cardiovascular disease (ASCVD) requiring additional lowering of LDL-C.\u00a0<\/p>\n\n\n\n

Other anti-cholesterol therapies such as Praluent<\/strong> and Repatha<\/strong>, which are administered intravenously, Nexletol will have the upper hand in terms of convenient administration route. Moreover, Esperion\u2019s drug will cost comparatively lesser than the other available in the market and will be rolled in the market in March. <\/p>\n\n\n\n

The company is also hoping for positive results for its another LDL-C lowering medicine – bempedoic acid and ezetimibe combination tablet \u2013 known for reducing low-density lipoprotein cholesterol and cholesterol absorption respectively. <\/p>\n\n\n\n

Karius \u2013 a California-based start-up – focused on liquid biopsy tests – has raised USD 165 Million in Series B round.<\/strong><\/h2>\n\n\n\n

The round was led by SoftBank Vision Fund 2 along with the participation from General Catalyst, HBM Healthcare Investments and existing investors Khosla Ventures and LightSpeed Venture Partners.<\/p>\n\n\n\n

Liquid biopsies have been gaining steam past years as they can easily detect foreign-derived biomarkers, genetic materials in body fluids \u2013 blood <\/a>and urine<\/a>, helping in detection of tumors, prenatal screening and others. The company, in the same way, is making tools to detect pathogens applying DNA sequencing and machine learning techniques.
<\/p>\n","protected":false},"excerpt":{"rendered":"

Formerly known as eptinezumab, Lundbeck\u2019s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.\u00a0 With the green signal to Lundbeck, it becomes a new member […]<\/p>\n","protected":false},"author":1,"featured_media":8592,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18080,2058,18083,18084,349,18081,1193,18082,639,5789],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-8591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-eptinezumab","tag-esperion","tag-heterozygous-familial-hypercholesterolemia","tag-karius","tag-latest-pharma-news","tag-lundbecks-vyepti","tag-migraine","tag-migraine-treatment-market","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nFDA nod to Vyepti, Esperion\u2019s Nexletol and Karius Series B round<\/title>\n<meta name=\"description\" content=\"Vyepti is the very first intravenous medication to receive the approval for migrane and will be available to patients from April this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA nod to Vyepti, Esperion\u2019s Nexletol and Karius Series B round\" \/>\n<meta property=\"og:description\" content=\"Vyepti is the very first intravenous medication to receive the approval for migrane and will be available to patients from April this year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-25T11:16:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA nod to Vyepti, Esperion\u2019s Nexletol and Karius Series B round","description":"Vyepti is the very first intravenous medication to receive the approval for migrane and will be available to patients from April this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius","og_locale":"en_US","og_type":"article","og_title":"FDA nod to Vyepti, Esperion\u2019s Nexletol and Karius Series B round","og_description":"Vyepti is the very first intravenous medication to receive the approval for migrane and will be available to patients from April this year.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-25T11:16:20+00:00","article_modified_time":"2021-07-24T07:27:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius","name":"FDA nod to Vyepti, Esperion\u2019s Nexletol and Karius Series B round","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1.jpg","datePublished":"2020-02-25T11:16:20+00:00","dateModified":"2021-07-24T07:27:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Vyepti is the very first intravenous medication to receive the approval for migrane and will be available to patients from April this year.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-lundbeck-esperion-karius#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/25163551\/slide1-1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eptinezumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Esperion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Heterozygous Familial Hypercholesterolemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Karius<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lundbeck\u0092s Vyepti<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Eptinezumab<\/span>","<span class=\"advgb-post-tax-term\">Esperion<\/span>","<span class=\"advgb-post-tax-term\">Heterozygous Familial Hypercholesterolemia<\/span>","<span class=\"advgb-post-tax-term\">Karius<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lundbeck\u0092s Vyepti<\/span>","<span class=\"advgb-post-tax-term\">Migraine<\/span>","<span class=\"advgb-post-tax-term\">Migraine Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 25, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 25, 2020 4:46 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8591"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8591\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8592"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8591"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8591"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}